TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06334016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection
Study: NCT04709731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 30mg QD
Description: Ponatinib 30 mg tablet, taken orally once daily
Study: NCT05603962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual training
Description: Visual training is the main type of management for CI patients clinically; however, the existing training protocol required patients to make several visits to the clinic for visual training, which might increase the burden for patients and result in higher failures in training. Therefore, this study will use a simple training method by utilizing prisms for CI patients to train at home, then compare visual symptoms and binocular vision after the training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual training
Description: Visual training is the main type of management for CI patients clinically; however, the existing training protocol required patients to make several visits to the clinic for visual training, which might increase the burden for patients and result in higher failures in training. Therefore, this study will use a simple training method by utilizing prisms for CI patients to train at home, then compare visual symptoms and binocular vision after the training.
Study: NCT05551403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyes-closed rest-EEG registration
Description: Recording of spontaneous brain activity while eyes are shut for the duration of 7 minutes using a tablet with instructions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation during EEG and EMG registrations
Description: Recording of TMS-evoked EEG and EMG responses according to various stimulation protocols

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photic stimulation during eyes-closes EEG registration
Description: Recording of visual evoked potentials in the EEG during flash stimulation by light-emitting diode (LED) goggles (while eyes are closed)
Study: NCT05161351

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Placebo tablets will be vitamin D3, (colecalciferol).
Study: NCT06413173

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Active tDCS and Cognitive Training Intervention
Description: Cognitive training will occur concurrently with active tDCS session. The cognitive training occurs on a computer and consists of 5 exercises specifically selected and scientifically supported to (i) place demands on the executive function system (e.g. working memory, behavioral inhibition, decision making, and set- shifting), (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across visual and auditory modalities During each 45-minute training period, participants will complete the daily assigned adaptive training module. Following the completion of training sessions 1, 5, and 10, participants will be asked to supply a subjective workload assessment.

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS and Cognitive Training Intervention
Description: Cognitive training will occur concurrently with sham tDCS session. The cognitive training occurs on a computer and consists of 5 exercises specifically selected and scientifically supported to (i) place demands on the executive function system (e.g. working memory, behavioral inhibition, decision making, and set- shifting), (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across visual and auditory modalities During each 45-minute training period, participants will complete the daily assigned adaptive training module. Following the completion of training sessions 1, 5, and 10, participants will be asked to supply a subjective workload assessment.
Study: NCT06346262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART RM
Description: The SMART-RM will consist of 8 group-format, 45-60 minute sessions (up to 11 participants per group), which will be collaboratively delivered by a Nurse Educator (NE) and a Peer Educator (PE).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valtoco Nasal Product
Description: Medication dosing will follow recommendations in the Valtoco package insert and managed by the epilepsy clinician.
Study: NCT04886804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zongertinib
Description: zongertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zongertinib
Description: zongertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zongertinib
Description: zongertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zongertinib
Description: zongertinib
Study: NCT06603493

Intervention type: OTHER
Intervention: Assessment of Central Sensitization
Description: Central sensitization will be assessed with the Central Sensitization Inventory

Intervention type: OTHER
Intervention: Assessment of depression, anxiety and stress levels
Description: Depression, anxiety and stress levels will be assessed using the Depression, Anxiety, Stress Scale (DASS-21)

Intervention type: OTHER
Intervention: Assessment of depression, anxiety and stress levels
Description: Depression, anxiety and stress levels will be assessed using the Depression, Anxiety, Stress Scale (DASS-21)
Study: NCT06248710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Syntocinon nose spray is usually applied in the context of labour and breast feeding. In this study, however, it will be used to induce an oxytocin (OT) release. Participants will apply three sprays in each nostril which will result in a dose of 24 I.U of oxytocin per participant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Syntocinon nose spray is usually applied in the context of labour and breast feeding. In this study, however, it will be used to induce an oxytocin (OT) release. Participants will apply three sprays in each nostril which will result in a dose of 24 I.U of oxytocin per participant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-Assisted Intervention
Description: The dogs involved in the study are trained and used to work with different people in animal-assisted interventions. The dog will be familiarized with the room and the material as well as the staff of the study. The dog will be specifically trained for this study. The dog will be involved for a maximum of 3 sessions per day (approx. 20 minutes in total) and 2 days per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-Assisted Intervention
Description: The dogs involved in the study are trained and used to work with different people in animal-assisted interventions. The dog will be familiarized with the room and the material as well as the staff of the study. The dog will be specifically trained for this study. The dog will be involved for a maximum of 3 sessions per day (approx. 20 minutes in total) and 2 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo nose spray contains a saltwater solution and will be applied like the Syntocinon nose spray containing oxytocin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo nose spray contains a saltwater solution and will be applied like the Syntocinon nose spray containing oxytocin.
Study: NCT06611306

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DE-iPTV
Description: Dose-escalated VMAT-based radiotherapy, as previously described in our planning study
Study: NCT05692011

Intervention type: DEVICE
Intervention: blood purification(PS)
Description: After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with PS membrane, 24 hours per day, for 3 consecutive days

Intervention type: DEVICE
Intervention: blood purification(AN69ST)
Description: After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with AN69ST membrane, 24 hours per day, for 3 consecutive days
Study: NCT06592001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atala™ lead
Description: Subjects will receive the Atala™ lead being evaluated in the study.
Study: NCT06671119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastric Mucosal Ablation (GMA)
Description: Endoscopic Gastric Mucosal Ablation (GMA) after sleeve gastrectomy
Study: NCT06675916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG Block with lidocaine hydrochloride
Description: Intervention is ultrasound-guided PENG block analgesia with lidocaine hydrochloride

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular infiltration with lidocaine hydrochloride
Description: Intervention is intra-articular analgesia with lidocaine hydrochloride
Study: NCT06673693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: SBRT
Study: NCT06673888

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin modified glass ionomer
Description: Resin modified glass ionomer (RMGI) is utilized for a variety of purposes, as luting agents, liners/bases, and restorative materials. The RMGI is more aesthetically pleasing than the conventional glass ionomer while maintaining the clinical benefits of the former, such as the release of fluoride, recharging capabilities, prevention of decalcification of hard tooth tissue, inhibition of bacterial acid metabolism, and ease of clinical operation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alkasite based restorative material
Description: Cention forte is bioactive restorative material which has the ability to remineralize hard dental tissues through calcium and fluoride release and can also neutralize bacterial acids through hydroxide ions release.
Study: NCT06598761

Intervention type: COMBINATION_PRODUCT
Intervention: Immunotherapy+radiotherapy
Description: Adjuvant Immunotherapy: Immunotherapy drug of choice is tirilizumab, which has received national recommendations in metastatic uroepithelial cancer. Tirelizumab 200mg Q3w; the duration of immunotherapy is recommended for at least 1 year.~Adjuvant radiotherapy can be given concurrently or sequentially with adjuvant immunotherapy; it is recommended that radiotherapy can be started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT), daily image-guided radiotherapy (Daily IGRT) techniques are used.

Intervention type: OTHER
Intervention: surveillance alone
Description: Patients recieve surveillance alone without any adjuvant interventions until any disease progression endpoints occur.
Study: NCT06610890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: One 15mg tablet, four tablets at a time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam maleate
Description: One 15mg tablet, one tablet at a time
Study: NCT05373901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab Beta
Description: Dinutuximab beta was administered intravenously at a dosage of 10 milligrams/ meters squared (mg/m2) per day for 10 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis-Retinoic Acid
Description: 13-cis-Retinoic Acid was administered orally at a daily total dose of 160 mg/m2, divided into approximately two equal doses given twice daily for 14 days following the conclusion of dinutuximab beta infusion.
Study: NCT05566678

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette
Description: Subjects who self-selected to continue smoking their own preferred brand of commercially available cigarettes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS
Description: Subjects who self-selected to quit smoking during the study duration will switch from cigarettes to using THS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Abstinence
Description: Subjects who self-selected to quit smoking may be prescribed Nicotine Replacement Therapy (NRT) to support them in remaining abstinent from use of any tobacco and nicotine containing products during the study. (Behavioral support will be provided to subjects to aid with abstinence.)
Study: NCT06334016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis sativa Extract
Description: Vape THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis sativa Extract
Description: Vape THC
Study: NCT04963712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zadaxin
Description: 1.6 mg subcutaneous injection, once a day in the first 2 weeks, and 1.6 mg subcutaneous injection, twice a week in the successive 22 weeks.
Study: NCT04513132

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active-dTMS
Description: The dTMS using H-coil with 5Hz stimulate ACC. The sessions of dTMS will be conducted twice daily for 5 consecutive days, and twice sessions of a day will be separated by 3 hours at least.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active-dTMS
Description: The dTMS using H-coil with 5Hz stimulate ACC. The sessions of dTMS will be conducted twice daily for 5 consecutive days, and twice sessions of a day will be separated by 3 hours at least.
Study: NCT06334016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis sativa Extract
Description: Vape THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Vape active nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Vape active nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Vape active nicotine
Study: NCT05933824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-98 injection
Description: Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-98 injection
Description: Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-98 injection
Description: Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-98 injection
Description: Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-98 injection
Description: Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-98 injection
Description: Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-98 injection
Description: Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-98 injection
Description: Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-98 injection
Description: Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-98 injection
Description: Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-98 injection
Description: Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Study: NCT05150145

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherpy will be performed to thoracic and liver metastasis after chemotherapy.
Description: Intensity modulated radiotherapy will be performed to liver metastasis and thoracic SCLC patients who achieved CR or PR after chemotherapy .
Study: NCT06403046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraarticular injection
Description: all patients will be subjected to routine (TMJ) arthrocentesis followed by Tenoxicam injection into the superior joint space in the (Tx group) and Meloxicam injection among the patients of (Mx group).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraarticular injection
Description: all patients will be subjected to routine (TMJ) arthrocentesis followed by Tenoxicam injection into the superior joint space in the (Tx group) and Meloxicam injection among the patients of (Mx group).
Study: NCT04933695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Oral tablet
Study: NCT06334016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Vape placebo nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Vape placebo nicotine
Study: NCT05597098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: 0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: 0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
Study: NCT05263141

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retro-auricular single-site endoscopic thyroidectomy
Description: The strap muscles and the sternocleidomastoid muscle were separated. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified，A lobe of thyroid specimen and central lymph nodes were dissected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional open surgery thyroidectomy
Description: The strap muscles were separated in the midline to expose the thyroid gland. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified， a lobe of thyroid specimen and central lymph nodes were dissected.
Study: NCT06129903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences.
Description: The primary intervention in this study is referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences. This study will not dictate specific psychiatry interventions beyond providing the referral.
Study: NCT06673576

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Complete crown technique for superimposition
Description: the complete crown technique, the crown of the tooth corresponding to the gingival margin under evaluation will be selected using the paint method and circular selection tool. The same selection process will be applied to the moving model.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gold standard technique for superimposition
Description: the gold standard technique, adjacent intact teeth and a portion of the palatal gingiva will be selected. Superimpositions will be executed utilizing the software's iterative closest point algorithm (ICP).
Study: NCT06548009

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics and other blood samples
Description: Blood samples taken with the objective of identifying a diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics and other blood samples
Description: Blood samples taken with the objective of identifying a diagnostic test
Study: NCT06334016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Vape placebo nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05599360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyxeos
Description: Vyxeos (daunorubicin and cytarabine) liposome for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylotarg
Description: Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal antibody (hP67.6; recombinant humanized immunoglobulin \[Ig\] G4, kappa antibody produced by mammalian cell culture in non-secreting 0 (NS0) cells) that is covalently linked to the cytotoxic agent N-acetyl gamma calicheamicin. Gemtuzumab ozogamicin consists of conjugated and unconjugated gemtuzumab. The conjugated molecules differ in the number of activated calicheamicin derivative moieties attached to gemtuzumab. The number of conjugated calicheamicin derivatives per gemtuzumab molecule ranges from predominantly zero to 6, with an average of 2 to 3 moles of calicheamicin derivative per mole of gemtuzumab.
Study: NCT06448572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXL01
Description: 1 capsule / day
Study: NCT04965883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision and Grafting
Description: reconstruction of deep burn by grafting

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dressing then delayed grafting
Description: multiple dressing and delayed grafting
Study: NCT04740255

Intervention type: DEVICE
Group type: OTHER
Intervention: Straberi Epistamp
Description: The patient's entire face will be treated. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm

Intervention type: DEVICE
Group type: OTHER
Intervention: Straberi Epistamp
Description: The patient's entire face will be treated. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm
Study: NCT05153174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: This is an over-the counter nutritional supplement. Participants will be given the extra strength tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: This is an over-the counter nutritional supplement. Participants will be given the extra strength tablets.
Study: NCT05665855

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone monoester
Description: A commercial liquid ketone monoester supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone monoester
Description: A commercial liquid ketone monoester supplement.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A liquid placebo that is taste-matched to the ketone monoester supplement.